Attention:

Certain features of Sigma-Aldrich.com will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.




 

BioFiles Volume 5, Number 3 — Vaccine Adjuvants

Download BioFiles v5 n3 (2.2 Mb PDF)

 

Table of Contents

 


Vaccine Media

 


EX-CELL EBx Media — Accelerate Your Vaccine Development

Background
Human and veterinary vaccines have typically been manufactured using chicken eggs and primary Chicken Embryo Fibroblasts (CEFs) (Table 1). These cell substrates pose a number of limitations including risk of insufficient supply, time-consuming processes with inconsistent yields, high costs of manufacture, the potential for allergic responses to egg-components and concerns associated with using bovine sera in CEF cultures.


Human Health Animal Health
  Avian Swine, Equine, Bovine Cat, Dog
Influenza virus Influenza virus Influenza virus (swine, equine) Canine distemper virus
Measles virus Reovirus Eastern equine encephalitis virus Canine parainfluenza virus
Rabies virus Fowlpox virus Western equine encephalitis virus  
Mumps virus Wild type & recombinant poxviruses (canary, chicken, pigeon...) Equine encephalomyelitis virus  
Rubella virus Egg drop syndrome virus    
Avian oncolytic viruses (NDV / IBDV...) Newcastle disease virus Bovine parainfluenza virus  
Smallpox virus (Lister, Vaccinia...) Infectious bursal desease virus Bovine lbaraki virus  
Recombinant poxvirus (ALVAC, MVA, FP...) Avian adenovirus (type I, II & III) Rabies virus  
Tick-borne encephalitis virus Polyoma virus (type I & II) Swine japanese encephalitis virus  
Yellow fever virus Herpes virus (pigeon, turkey, falcon, psittacine...)    
Sindbis virus Infectious bronchitis virus    
Semliki forest virus Encephalomyelitis virus    
Venezuelan EEV virus Anemia virus (chicken...)    
  Marek's disease virus    
Venezuelan EEV virus Marek's disease virus    
  Parvovirus (duck)    
Table 1. Vaccines produced in chicken eggs or CEFs.

 

Fully Documented Stable EB66® Cell Line Growth in Serum-free Media
A fully documented stable duck cell line termed EB66 cell line derived from embryonic stem cells has been established by and is owned by Vivalis (www.vivalis.com) as a superior alternative for the cost-effective manufacturing of vaccines currently produced in CEFs or eggs. EB66 cells maintain genetic stability, are immortal and grow in serum-free media. An added advantage is high density growth as suspension cells without the need for microcarriers.

Scaleable, Optimized Media
To support the EB66 cell line, SAFC Biosciences® has developed EX-CELL EBx media and supplements optimized for use with suspension EB66 cells to ensure maximum growth and high titer viral vaccine production. High cell viability and high cell density growth in suspension provides the optimal environment for high titer viral vaccine production.

Consistent High Viral Titers
Typical titer values range from 8–9 log TCID50/mL, when using EB66 cells grown in EX-CELL EBx medium and infected with modified vaccinia virus Ankara (MVA) in stirred tank bioreactors.

Accelerate your timelines by ensuring successful runs time after time.

Economical, Consistent, Scaleable and Highly Robust, EX-CELL EBx Media Maximizes Vaccine Production

  • High density suspension cultures.
  • No microcarriers or detachment factors required.
  • Robust, consistent, scaleable process.
  • Animal-component free, serum- free media optimized for growth and productivity of EB66 cells.
  • Efficient replication of a broad range of viruses (influenza, poxvirus, measles, etc.).

Technical Assistance
For EX-CELL EBx media support and information, please contact our scientists who have expertise and hands-on experience with EB66 cells. For EB66 cell line and viral production process development information, please contact Vivalis.

EX-CELL EBx Cell Line Media Products

 


EX-CELL Vaccine Media

Cultured cells have long been known to serve as excellent hosts for propagation of many types of viruses. The ability of cell culture systems to produce large quantities of attenuated viral particles has served as the basis for the production of both human and veterinary vaccines. Traditional methods have relied on the production of viral agents in cells cultured in medium supplemented with serum, most commonly fetal bovine serum. The animal serum in cell cultures used in production processes can cause a number of problems for manufacturers. The increased costs of raw materials and post-production processing associated with serum have prompted interest in the development of serum-free media for vaccine production. More recently, the potential for contamination by adventitious agents present in serum has heightened regulatory concerns regarding the use of animal-derived components in media used for pharmaceutical manufacturing. With these factors in mind, Sigma has developed new media for vaccine production with reduced levels or completely devoid of animal-derived components.

EX-CELL Vaccine Media Products

 


Classical Media

Traditionally viruses for seasonal influenza vaccines have been grown in eggs over a number of months. Recently influenza vaccine development has used cell culture techniques for virus growth in living cells instead of the time-consuming egg-based process of the past.

Classical Media Products

 


Serum

Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture media because of its high content of embryonic growth promoting factors. When used at appropriate concentrations it supplies many defined and components that have been shown to satisfy specific metabolic requirements for the culture of cells in vitro.

Sigma-Aldrich continues its commitment to the life science researcher by providing over 30 years of fetal bovine serum production and manufacturing. We offer a variety of origins with special treatments and specifications along with a dependable, consistent supply that is ISO certified quality from collection to finished product.

Serum Products

back to top